DEF 14A: BioCardia Seeks Stockholder Approval for Reverse Stock Split to Regain Nasdaq Compliance

BioCardia is asking stockholders to approve a reverse stock split and other corporate governance matters at its upcoming annual meeting to maintain its Nasdaq listing and for other corporate purposes.

Summary

• BioCardia, Inc. is holding its 2024 annual meeting of stockholders on May 20, 2024, to vote on several key proposals.
• The proposals include the election of two Class II directors, ratification of the appointment of PKF San Diego, LLP as the independent registered public accounting firm, a non-binding vote on executive compensation, and approval of an amendment to effect a reverse stock split of the company's common stock.
• The proposed reverse stock split would be at a ratio of 1-for-2 to 1-for-20, to be determined by the board of directors, and would also reduce the number of authorized shares of common stock from 100,000,000 to 50,000,000.
• The board of directors recommends voting FOR all proposals.
• The record date for determining stockholders eligible to vote at the Annual Meeting is April 15, 2024.
• The company is facing potential delisting from Nasdaq due to not meeting the minimum bid price and market value of listed securities requirements.
• The board believes a reverse stock split is a potentially effective means to maintain compliance with Nasdaq listing requirements.
• If the reverse stock split is approved but not implemented within one year, the board will seek stockholder approval again before implementing it.
• The company is also asking for a non-binding vote on executive compensation.

Sentiment

Score: 5

Explanation: The document is primarily informational, outlining the proposals for the annual meeting. The need for a reverse stock split indicates financial challenges, but the board is taking steps to address them.

Positives

• The board of directors is taking proactive steps to address Nasdaq listing deficiencies.
• Maintaining a Nasdaq listing is expected to improve the company's access to capital and increase investor interest.
• The company has a formal policy for reviewing related party transactions to ensure fairness and transparency.
• The company has change of control and severance agreements with its executive officers.

Negatives

• The company is currently not in compliance with Nasdaq's minimum bid price and market value of listed securities requirements.
• There is no guarantee that the reverse stock split will increase the market price of the common stock or maintain compliance with Nasdaq listing requirements.
• A reverse stock split may result in some stockholders owning odd lots of less than 100 shares, which may be more difficult to sell.
• The company has incurred net losses in the past two fiscal years.

Risks

• Failure to regain compliance with Nasdaq listing requirements could result in delisting, which may adversely affect the company's ability to raise capital and the liquidity of its stock.
• The reverse stock split may not result in a sustained increase in the stock price.
• The market price of the common stock is dependent on many factors, including our business and financial performance, general market conditions, prospects for future growth and other factors detailed from time to time in the reports we file with the SEC.
• The total market capitalization of our common stock after a Reverse Stock Split may be lower than the total market capitalization before a Reverse Stock Split and, in the future, the market price of our common stock following a Reverse Stock Split may not exceed or remain higher than the market price prior to a Reverse Stock Split.

Future Outlook

The company intends to implement the Reverse Stock Split and will determine the ratio of the Reverse Stock Split, in the range of between 1-for-2 and 1-for-20, inclusive, as determined in the judgment of our board of directors.

Industry Context

Many small-cap biotech companies face challenges in maintaining Nasdaq listing compliance due to volatile stock prices and the need for significant capital to fund research and development. Reverse stock splits are a common tool used by these companies to regain compliance and maintain access to public markets.

Comparison to Industry Standards

• Reverse stock splits are a relatively common practice among companies facing delisting from major exchanges.
• Comparable companies that have recently undertaken reverse stock splits include [hypothetical company A] and [hypothetical company B].
• The success of a reverse stock split in maintaining listing and improving stock price varies widely and depends on the company's underlying fundamentals and market conditions.

Related Party Transactions

• In June 2023, certain directors and executive officers of the Company invested in a registered direct offering of common stock.
• In February 2024, Peter Altman, our President and Chief Executive Officer, invested in a private placement of common stock and warrants.

Stakeholder Impact

• The reverse stock split could impact shareholders by reducing the number of shares they own and potentially affecting the stock price.
• Failure to maintain Nasdaq listing could negatively impact shareholders due to reduced liquidity and access to capital.
• Employees and other stakeholders could be affected by the company's financial performance and ability to execute its business plan.

Next Steps

• Stockholders will vote on the proposals at the Annual Meeting on May 20, 2024.
• The board of directors will determine the ratio for the reverse stock split if approved.
• The company will file the Reverse Stock Split Amendment with the Secretary of State of the State of Delaware promptly after the Annual Meeting at a ratio to be determined by our board of directors within the range of ratios approved by the stockholders at the Annual Meeting, and, if the Reverse Stock Split is effected, a reduction in the number of authorized shares of common stock from 100,000,000 shares to 50,000,000 shares.

Key Dates

Keywords

reverse stock split, Nasdaq compliance, annual meeting, proxy statement, director election, executive compensation, PKF San Diego, BioCardia